Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
about
Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome.Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.Microbial nucleic acids pay a Toll in kidney disease.Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.Phenotypic and functional heterogeneity of human memory B cells.TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae.DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivoThe effect of CpG-oligodeoxynucleotides with different backbone structures and 3' hexameric deoxyriboguanosine run conjugation on the treatment of asthma in mice.Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity.Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9.Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity.Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus.The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters.Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients.Porcine circovirus type 2 DNA influences cytoskeleton rearrangements in plasmacytoid and monocyte-derived dendritic cells.B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus.Impaired IFN-α secretion by plasmacytoid dendritic cells induced by TLR9 activation in chronic idiopathic urticaria.
P2860
Q34017633-5DCFE64F-7EBF-42EC-A656-F5A33604C1CAQ34103317-3205ECE2-B18B-4D43-8496-66293A2836A9Q36423215-FA41CA07-9A92-4EC4-9CD1-00AC38FA9714Q36441718-025CFFE4-D393-4C57-A58A-2858902E84DCQ36793158-53EA637A-F152-4F54-A479-B6932307B7F9Q37079426-8C48097E-ECDF-41FB-A7F1-CE5F92A3D4C7Q37214782-C71E1BF0-4783-4DA6-A20C-549B73EFF8E1Q37270799-4E74979E-064A-438E-89A6-5DEAC9E05C00Q37364531-0A67C982-9555-4B2B-9B0C-C0F7E66E36FEQ37758263-06AA8C87-0D20-4014-A3BC-E51D2F47BD13Q37956536-4ABF155D-7382-4551-ADFA-F503E64DFB57Q38333329-F592712E-BE3C-421A-8DB2-BB61CDDDA98CQ40062305-4FF79304-2AC6-4B1A-9DE8-1BEAF734688FQ41943280-16047194-6159-413F-8C48-596E8FA2F697Q41944686-B5F842FE-9AD3-4353-943F-93EBE988B1AFQ41945144-B047DA8C-E460-46FC-9AFE-9E059BD3A9CDQ52603615-1B473AAA-CABF-42EA-B3F0-7C9D6930E7EDQ53314342-D8817580-3673-4E9D-89D0-E0FF1DA3E8BAQ54394473-20AD3BFE-A5A1-4D6C-9EC9-5CCA40D98585
P2860
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@ast
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@en
type
label
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@ast
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@en
prefLabel
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@ast
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@en
P2860
P1476
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
@en
P2093
P2860
P356
10.1111/J.1365-2249.2004.02728.X
P577
2005-04-01T00:00:00Z